Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED).

Background: The purpose of this study was to examine the removal of meropenem during an 8-h sustained low-efficiency dialysis (SLED) session. Using a minimum inhibitory concentration (MIC) = 2 microg/mL as our reference point, we also evaluated the therapeutic adequacy of dosing meropenem as 1 g every 12 h during SLED.

Methods: This was a prospective, open-label study involving 10 intensive care unit patients with renal failure needing SLED.

Removal of vancomycin in sustained low-efficiency dialysis (SLED): a need for better surveillance and dosing.

Aims: This study was designed to evaluate the extent of vancomycin removal from the blood compartment during sustained low-efficiency dialysis (SLED) and the efficacy of our current vancomycin dosing practice.

Material: 10 ICU patients were selected. They all had oliguric renal failure requiring SLED and were on vancomycin therapy.